98 related articles for article (PubMed ID: 21477928)
21. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
22. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
Lee JH; Glick HA; Hayman JA; Solin LJ
J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
[TBL] [Abstract][Full Text] [Related]
23. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
26. Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.
Gogate A; Wheeler SB; Reeder-Hayes KE; Ekwueme DU; Fairley TL; Drier S; Trogdon JG
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409255
[TBL] [Abstract][Full Text] [Related]
27. Health care-related time costs in patients with metastatic breast cancer.
Rocque GB; Williams CP; Ingram SA; Azuero A; Mennemeyer ST; Young Pierce J; Nipp RD; Reeder-Hayes KE; Kenzik KM
Cancer Med; 2020 Nov; 9(22):8423-8431. PubMed ID: 32955793
[TBL] [Abstract][Full Text] [Related]
28. Financial burden among metastatic breast cancer patients: a qualitative inquiry of costs, financial assistance, health insurance, and financial coping behaviors.
Waters AR; Petermann VM; Planey AM; Manning M; Spencer JC; Spees LP; Rosenstein DL; Gellin M; Padilla N; Reeder-Hayes KE; Wheeler SB
Cancer Causes Control; 2024 Jun; 35(6):955-961. PubMed ID: 38388859
[TBL] [Abstract][Full Text] [Related]
29. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Liu X; Reeder-Hayes KE; Rotter J; Ekwueme DU; Wheeler SB
Cancer; 2020 Sep; 126(18):4118-4125. PubMed ID: 32648979
[TBL] [Abstract][Full Text] [Related]
30. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system.
Rashid N; Koh HA; Baca HC; Lin KJ; Malecha SE; Masaquel A
Breast Cancer (Dove Med Press); 2016; 8():173-181. PubMed ID: 27785099
[TBL] [Abstract][Full Text] [Related]
31. An economic evaluation of the optimal workload in treating surgical patients in a breast unit.
Pagano E; Ponti A; Gelormino E; Merletti F; Mano MP
Eur J Cancer; 2003 Apr; 39(6):748-54. PubMed ID: 12651199
[TBL] [Abstract][Full Text] [Related]
32. How can policy makers use available evidence on the cost benefits of drug treatement?
Godfrey C; Parrott S
J Ment Health Policy Econ; 2000 Mar; 3(1):55. PubMed ID: 11967437
[TBL] [Abstract][Full Text] [Related]
33. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Montero AJ; Eapen S; Gorin B; Adler P
Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
[TBL] [Abstract][Full Text] [Related]
34. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer.
Pouwels XGLV; Ramaekers BLT; Joore MA
Breast Cancer Res Treat; 2017 Oct; 165(3):485-498. PubMed ID: 28689361
[TBL] [Abstract][Full Text] [Related]
35. Economic burden of cancer across the European Union: a population-based cost analysis.
Luengo-Fernandez R; Leal J; Gray A; Sullivan R
Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
[TBL] [Abstract][Full Text] [Related]
36. Analysis of hospitalizations by cardiovascular disease in the population with diabetes in Spain.
Zapatero-Gaviria A; Gómez-Huelgas R; Canora-Lebrato J; Ena-Muñoz J; Romero-Sánchez M; Mendez-Bailón M; Marco-Martínez J; Barba-Martín R
Rev Clin Esp (Barc); 2019 Apr; 219(3):124-129. PubMed ID: 30447849
[TBL] [Abstract][Full Text] [Related]
37. Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update.
Gomez-Peralta F; Escalada San Martín FJ; Menéndez Torre E; Mata Cases M; Ferrer García JC; Ezkurra Loiola P; Ávila Lachica L; Fornos Pérez JA; Artola Menéndez S; Álvarez-Guisasola F; Rica Echevarría I; Girbés Borrás J;
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):611-624. PubMed ID: 30366843
[TBL] [Abstract][Full Text] [Related]
38. Indirect costs associated with metastatic breast cancer.
Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
[TBL] [Abstract][Full Text] [Related]
39. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
